To include your compound in the COVID-19 Resource Center, submit it here.

Orexigen falls on Contrave update

Orexigen Therapeutics Inc. (NASDAQ:OREX) lost $1.06 (33%) to $2.12 on Friday after suspending all of its obesity programs in the U.S. following FDA's request for a larger-than-expected cardiovascular

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE